title: A new hope for precision medicine.
abstract: The SS1P immunotoxin is combined with immunomodulatory therapy in order to improve its efficacy in human mesothelioma (Hassan et al., this issue).
authors.affiliation: Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA.
authors.forename: Ravi
authors.initials: R
authors.lastname: Salgia
authors.forename: Martin
authors.initials: M
authors.lastname: Sattler
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005260:Female; D058851:GPI-Linked Proteins / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy; D008297:Male; D000090204:Mesothelin; D008654:Mesothelioma / Q000276:immunology* / Q000628:therapy*; D010534:Peritoneal Neoplasms / Q000276:immunology* / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D058851:GPI-Linked Proteins; C474515:SS1(dsFv)PE38; D000090204:Mesothelin